Haas, Kelsey M. http://orcid.org/0000-0002-1463-6726
McGregor, Michael J.
Bouhaddou, Mehdi
Polacco, Benjamin J. http://orcid.org/0000-0003-1570-9234
Kim, Eun-Young http://orcid.org/0000-0002-7436-7396
Nguyen, Thong T.
Newton, Billy W.
Urbanowski, Matthew
Kim, Heejin
Williams, Michael A. P.
Rezelj, Veronica V.
Hardy, Alexandra
Fossati, Andrea
Stevenson, Erica J.
Sukerman, Ellie
Kim, Tiffany http://orcid.org/0000-0001-8386-7686
Penugonda, Sudhir
Moreno, Elena http://orcid.org/0000-0002-2301-4558
Braberg, Hannes http://orcid.org/0000-0002-7070-2257
Zhou, Yuan
Metreveli, Giorgi
Harjai, Bhavya
Tummino, Tia A. http://orcid.org/0000-0001-9155-820X
Melnyk, James E. http://orcid.org/0000-0003-1915-8089
Soucheray, Margaret http://orcid.org/0000-0002-0370-6653
Batra, Jyoti
Pache, Lars http://orcid.org/0000-0002-4193-1042
Martin-Sancho, Laura
Carlson-Stevermer, Jared
Jureka, Alexander S.
Basler, Christopher F. http://orcid.org/0000-0003-4195-425X
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
Shoichet, Brian K. http://orcid.org/0000-0002-6098-7367
Shriver, Leah P.
Johnson, Jeffrey R.
Shaw, Megan L. http://orcid.org/0000-0002-1267-0891
Chanda, Sumit K. http://orcid.org/0000-0001-9399-7927
Roden, Dan M.
Carter, Tonia C. http://orcid.org/0000-0002-2107-7838
Kottyan, Leah C. http://orcid.org/0000-0003-3979-2220
Chisholm, Rex L.
Pacheco, Jennifer A. http://orcid.org/0000-0001-8021-5818
Smith, Maureen E. http://orcid.org/0000-0001-9480-1092
Schrodi, Steven J. http://orcid.org/0000-0003-2304-8528
Albrecht, Randy A. http://orcid.org/0000-0003-4008-503X
Vignuzzi, Marco
Zuliani-Alvarez, Lorena
Swaney, Danielle L. http://orcid.org/0000-0001-6119-6084
Eckhardt, Manon http://orcid.org/0000-0001-8143-6129
Wolinsky, Steven M.
White, Kris M. http://orcid.org/0000-0003-0889-0506
Hultquist, Judd F. http://orcid.org/0000-0001-6424-4280
Kaake, Robyn M.
García-Sastre, Adolfo http://orcid.org/0000-0002-6551-1827
Krogan, Nevan J. http://orcid.org/0000-0003-4902-337X
Article History
Received: 28 September 2022
Accepted: 31 August 2023
First Online: 27 September 2023
Competing interests
: The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. N.J.K. has previously held financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York and Twist Bioscience Corp. He currently has financially compensated consulting agreements with Maze Therapeutics, Interline Therapeutics, Rezo Therapeutics, and GEn1E Lifesciences, Inc. He is on the Board of Directors of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and Interline Therapeutics. The García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary, Synairgen and Pfizer, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and Astrazeneca. A.G.-S. is an inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. The Hultquist laboratory has received prior funding support from Gilead Sciences, and J.F.H. has a financially compensated consulting agreement with Merck. D.L.S. has a consulting agreement with Maze Therapeutics. M.B. is a financially compensated scientific advisor for GEn1E Life Sciences. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Rezo Therapeutics, Revolution Medicines, Type6 Therapeutics, Vevo, Vicinitas and Wellspring Biosciences (Araxes Pharma). J.C.-S. is a former employee and stockholder of Synthego. While not directly relevant to this study, C.F.B. is a scientific advisor for Axion BioSystems, M.L.S. has a financially compensated consulting agreement with Calibr, and S.P. is employed by Roivant Sciences, Inc. S.P. also holds stock compensation from Roivant Sciences and AbbVie. The remaining authors declare no competing interests.